Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

3816 results about "Autoimmune condition" patented technology

An autoimmune disease is a condition arising from an abnormal immune response to a normal body part. There are at least 80 types of autoimmune diseases. Nearly any body part can be involved. Common symptoms include low grade fever and feeling tired.

Pan-ras inhibitor compound

The present invention relates to a compound as shown in formula (A) having a pan-RAS inhibitory effect, or an isotopic derivative or stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound, and the use of the compound of formula (A) in the prevention and / or treatment of cancers, tumors, inflammatory diseases, autoimmune diseases or immune-mediated diseases.
Owner:ADLAI NORTYE BIOPHARMA CO LTD

Heterocyclic derivatives and use thereof in medicine

The present invention relates to heterocyclic derivatives and the use thereof in medicine, in particular to compounds represented by general formula (I) or stereoisomers, pharmaceutically acceptable salts or cocrystals and intermediates thereof, a preparation method therefor, and the use thereof in the preparation of drugs for treating autoimmune diseases or inflammatory diseases.
Owner:HAISCO PHARMACEUTICAL GROUP CO LTD

KLRB1 binding agents and methods of use thereof

KLRB1 binding agents (in particular anti-KLRB1 antibodies and antigen binding portion thereof) and compositions thereof, as well as therapeutic methods of using the agents, e.g., for depleting cells or inhibiting cells or activating cells (in particular, Th17, Th17.1, ex-Th17, Tc17, MAIT, INKT, peTh2, ILC2, ILC3, NK cells, and / or neoplastic T or NK cells in vivo), for the treatment of autoimmune disease, allergic diseases, transplant rejection, hematologic malignancies, and cancer.
Owner:THE BRIGHAM & WOMEN S HOSPITAL INC

Antibody binding to il-11, antigen-binding fragment thereof, and uses thereof

PCT designated stage expiredWO2024250838A1AntipyreticAnalgesicsAntigenAutoimmune condition
The present invention relates to the field of biomedicine, and specifically provides an antibody binding to IL-11 or antigen-binding fragment thereof, comprising three heavy-chain complementarity-determining regions respectively represented by HCDR1, HCDR2, and HCDR3, and three light-chain complementarity-determining regions respectively represented by LCDR1, LCDR2, and LCDR3, the antibody or antigen-binding fragment thereof being selected from A-I, A-II, A-III, or A-IV. The provided antibody or antigen-binding fragment thereof has high binding capacity to the IL-11 antigen and can block the IL-11 antigen from binding to receptors thereof, thus effectively inhibiting the pro-fibrotic effect of IL-11 and inhibiting or preventing the generation or proliferation of fibroblasts, and can be effectively used for treating or preventing human fibrotic diseases, inflammation, cancers, or autoimmune diseases.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

Compound having BTK protein degradation activity, and medical uses thereof

The present disclosure provides: a compound of a specific chemical structure, having excellent activity with respect to BTK degradation; or a pharmaceutically acceptable salt thereof. The present disclosure also provides a composition comprising the compound or pharmaceutically acceptable salts thereof. The present disclosure also provides are pharmaceutical use for treating or preventing BTK-associated diseases (for example, autoimmune diseases or cancer) of the compound, the salt thereof, and the composition comprising same according to the present disclosure. The present disclosure also provides a method for treating or preventing BTK-associated diseases (for example, autoimmune diseases or cancer), comprising administering, to a subject requiring treatment, an effective amount of the compound, the salt thereof, or the composition comprising same according to the present disclosure.
Owner:UBIX THERAPEUTICS

Bispecific CD19 / CD20-targeted chimeric antigen receptors and uses thereof

Various embodiments of the invention provide binding molecules for B-lymphocyte antigen (e.g., CD 19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD 19 and CD20). Embodiments of the invention also provide cells expressing such binding molecules, therapeutics compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigen (e.g., CD19 and CD20), including a hematologic cancer, an autoimmune disease (e.g., multiple sclerosis and systemic lupus erythematosus).
Owner:ATARA BIOTHERAPEUTICS INC

Antibody binding to IL-11, antigen binding fragment and application thereof

The present invention relates to the field of biological medicine, and particularly provides an IL-11 binding antibody or an antigen binding fragment thereof, the antibody comprises three heavy chain complementarity determining regions represented by HCDR1, HCDR2 and HCDR3 respectively and three light chain complementarity determining regions represented by LCDR1, LCDR2 and LCDR3 respectively, and the antibody or the antigen binding fragment thereof is selected from A-I, A-II, A-III or A-IV. The antibody or the antigen binding fragment thereof provided by the invention has relatively high binding capacity with the IL-11 antigen, and can block the binding of the IL-11 antigen and a receptor thereof, so that the fibrosis promoting effect of the IL-11 is effectively inhibited, the generation or proliferation of fibrocytes is inhibited or prevented, and the anti-fibrosis effect of the IL-11 is improved. The compound can be effectively used for treating or preventing human fibrosis diseases, inflammations, cancers or autoimmune diseases.
Owner:BEIJING DONGFANG BIOTECH CO LTD +1

CD25 antibodies

Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and / or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.
Owner:IBIO INC

1,3-dihydro-2h-pyrrolo[3,4-c]quinoline derivatives as CGAS inhibitors for the treatment of inflammatory and / or autoimmune diseases

The present invention relates to novel compounds, to said compounds for use as a medicine, more in particular for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to a method for the prevention or treatment of said diseases comprising the use of the novel compounds. The present invention furthermore relates to pharmaceutical compositions or combination preparations of the novel compounds as well as to said compositions or preparations for use as a medicine, more preferably for the prevention or treatment of diseases mediated by activity of cGAS, yet more in particular for the prevention or treatment of inflammation conditions or cancer. The present invention also relates to processes for the preparation of said compounds.
Owner:KATHOLIEKE UNIV LEUVEN +1

Use of dual-target car-t cells in treating b-cell autoimmune diseases

The use of dual-target CAR-T cells in treating systemic lupus erythematosus and other B-cell autoimmune diseases is provided. The first target of the chimeric antigen receptor is CD19, the second target is BCMA, and specifically, the chimeric antigen receptor is a chimeric antigen receptor with a Loop structure, which is shown as follow: L-VL, CD19-VH, BCMA-VL, BCMA-VH, CD19-H-TM-C-CD3ΞΆ; the BCMA-CD19 CAR-T cells transduced by the chimeric antigen receptor targeting CD19 and BCMA can completely block the pathway of producing autoantibodies, and completely cover the B cells, plasmablasts and plasma cells at multiple differentiation stages that produce autoantibodies, so that the dual-target CAR-T therapy designed based on this concept can be aimed at refractory SLE and is expected to achieve faster remission and deeper and lasting curative effect.
Owner:GRACELL BIOTECHNOLOGIES (SHANGHAI) CO LTD

Antibody specific to CD123 and antibody-drug conjugate, and use of the same

To provide an antibody specific to CD123 and an antibody-drug conjugate, and use thereof.SOLUTION: The present invention provides an antibody that specifically binds to CD123. The present invention further relates to an immune conjugate (e.g., antibody drug conjugate or ADC) including the antibody, nucleic acid encoding the antibody, and a method for obtaining the antibody. The present invention further relates to a therapeutic method regarding use of the antibody and ADC for treating symptoms related to a cell expressing CD123 (e.g., cancer or autoimmune disease).SELECTED DRAWING: Figure 1
Owner:PFIZER INC

Pharmaceutical formulation comprising Anti-ox40 monoclonal antibody

Disclosed is a pharmaceutical formulation including a monoclonal OX40 antibody, a buffer, a stabilizer, and a surfactant, which can maintain the stability under various scenarios, such as manufacturing, packaging, sub-packaging, shipping, administration, and / or storage. Also disclosed are the use of the pharmaceutical formulation in the preparation of a drug for treating OX40-associated diseases, in particular, inflammatory and / or autoimmune diseases, and a method for preparing the pharmaceutical formulation.
Owner:INMAGENE PTE LTD

Tricyclic compound, and preparation method therefor and use thereof

A tricyclic compound, and a preparation method therefor and the use thereof. The present invention relates to a compound as shown in general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating or preventing autoimmune diseases, inflammatory diseases, cancers, viral diseases, neurodegenerative diseases, genetic disorders, hormone-related diseases, metabolic disorders, organ-transplantation-related diseases, immunodeficiency disorders, destructive bone diseases, proliferative disorders, infectious diseases, cell-death-related conditions and cardiovascular diseases. Each substituent in general formula (I) is as defined in the description.
Owner:SHANGHAI HUILUN BIOLOGICAL TECH CO LTD

Disease modifying Anti-rheumatic drug combination therapies

PCT designated stage expiredWO2025099187A1AntipyreticDigestive systemAutoimmune conditionProgressive disorder
The invention provides combination therapies comprising disease modifying anti-rheumatic drugs and mitochondrial complex I modulator (MCIM) compounds, which find utility in the medical field of inflammatory and progressive disorders, for example autoimmune diseases such as arthritis.
Owner:ISTESSO 2 LTD

Dual inhibitors of amine oxidases and peroxidases, and uses thereof

PCT designated stage expiredWO2025107036A1Senses disorderOrganic chemistryAutoimmune conditionVasculitis
The present invention relates to novel compounds which are capable of inhibiting semicarbazide-sensitive amine oxidase and myeloperoxidase. These compounds are useful for the treatment of a variety of inflammatory indications, e.g., autoimmune diseases, respiratory disease, fibrosis, vasculitis, neurological diseases or disorders, and the complications resulting from infectious disease, obesity, diabetes / metabolic syndrome and / or cardiovascular disease in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.
Owner:SYNTARA LTD

Multi-specific antibody specifically binding to LIGHT and GM-CSFR alpha, and composition and application thereof

Relates to a multispecific antibody or antigen binding fragment specifically binding to LIGHT and GM-CSFR alpha, a composition containing the antibody or antigen binding fragment specifically binding to LIGHT and the antibody or antigen binding fragment specifically binding to GM-CSFR alpha, a pharmaceutical composition containing the multispecific antibody or composition, and a preparation method and application thereof. Including methods of using the same to prevent and treat inflammatory, respiratory or autoimmune diseases.
Owner:STAIDSON (BEIJING) BIOPHARMACEUTICALS CO LTD

Engineered mucosal-associated invariant t (MAIT) cells and methods of making and using thereof

Embodiments of the invention include compositions and methods related to engineered human mucosal-associated invariant T (eMAIT) cells for off-the-shelf use for clinical therapy for cancer, infectious, and autoimmune diseases. In some embodiments, the eMAIT cells are produced from healthy human donor peripheral blood, cord blood, or G-CSF mobilized peripheral blood. In particular embodiments, the eMAIT cells are produced from a pluripotent stem cell line and therefore can be of unlimited supply. In some embodiments, the eMAIT cells are engineered to express chimeric antigen receptors (CARs), or / and immune regulatory molecules, or / and allorejection resistance molecules. Embodiments of the invention also include compositions of matter comprising polynucleotides encoding mucosal-associated invariant T cell receptor alpha chain polypeptides and / or mucosal-associated invariant T cell receptor beta chain polypeptides.
Owner:RGT UNIV OF CALIFORNIA